bioAffinity Technologies, Inc. (BIAF)

NASDAQ: BIAF · IEX Real-Time Price · USD
2.470
-0.060 (-2.37%)
Jul 16, 2024, 11:42 AM EDT - Market open
-2.37%
Market Cap 29.84M
Revenue (ttm) 4.94M
Net Income (ttm) -8.37M
Shares Out 11.66M
EPS (ttm) -0.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 16,867
Open 2.580
Previous Close 2.530
Day's Range 2.470 - 2.590
52-Week Range 0.955 - 3.620
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Aug 12, 2024

About BIAF

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas. [Read more]

Sector Healthcare
IPO Date Sep 1, 2022
Employees 14
Stock Exchange NASDAQ
Ticker Symbol BIAF
Full Company Profile

Financial Performance

In 2023, BIAF's revenue was $2.53 million, an increase of 52627.44% compared to the previous year's $4,803. Losses were -$7.94 million, -2.66% less than in 2022.

Financial Statements

News

Biotricity and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / July 12, 2024 / RedChip Companies will air interviews with Biotricity, Inc. (Nasdaq:BTCY) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks, Big M...

Other symbols: BTCY
4 days ago - Accesswire

bioAffinity Technologies Reports 217% Sales Growth in Second Quarter 2024 for CyPath® Lung

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies raises the 2024 full-year forecast for sales of CyPath Lung, a noninvasive test for lung cancer, by 85%.

7 days ago - Business Wire

BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / July 5, 2024 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks, Big Money™...

Other symbols: BIVI
11 days ago - Accesswire

bioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath® Lung Tests

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports a 139% growth in the number of pulmonology practices and physicians ordering CyPath Lung for their patients.

4 weeks ago - Business Wire

bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technology reports record Q1 2024 revenue driven by accelerating sales of lung cancer diagnostic CyPath Lung.

2 months ago - Business Wire

bioAffinity Technologies News Update

SAN ANTONIO--(BUSINESS WIRE)-- #ATS--bioAffinity reports ramp in sales of CyPath® Lung, expanded sales team, new Patient Coach and upcoming presentation at American Thoracic Society.

2 months ago - Business Wire

bioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of Growth

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies is developing diagnostics based on its proprietary platform for use with BAL fluid to detect lung cancer and to detect COPD.

2 months ago - Business Wire

bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening

SAN ANTONIO--(BUSINESS WIRE)-- #ACS--bioAffinity Technologies and the American Cancer Society are expanding their campaign to raise funds for lung cancer screening.

3 months ago - Business Wire

bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports fourth quarter and full year 2023 financial results.

3 months ago - Business Wire

Wallachbeth Capital Announces Closing of bioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement

JERSEY CITY, N.J. , March 8, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, In...

4 months ago - PRNewsWire

bioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies closed a securities purchase agreement with institutional investors for gross proceeds of approximately $2.5 million.

4 months ago - Business Wire

WallachBeth Capital Announces Pricing of BioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement

JERSEY CITY, N.J. , March 6, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that BioAffinity Technologies (NA...

4 months ago - PRNewsWire

bioAffinity Technologies Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces it has entered into a securities purchase agreement with institutional investors.

4 months ago - Business Wire

bioAffinity Technologies Reports Accelerating Sales Growth of CyPath® Lung

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports 375% growth in sales of CyPath Lung tests in recent months.

4 months ago - Business Wire

Medical Director of Lung Innovations Network and The Lung Center at Penn Highlands Healthcare, Sandeep Bansal, M.D., Joins bioAffinity Technologies' Medical and Scientific Advisory Board and Incorporates CyPath® Lung into Medical Practice

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Sandeep Bansal, M.D., joins bioAffinity Medical and Science Advisory Board; adds CyPath Lung to his practice.

5 months ago - Business Wire

bioAffinity Technologies In The News

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Summary of the latest news about bioAffinity Technologies.

6 months ago - Business Wire

bioAffinity Technologies Announces Award of Therapeutic Patent for Treatment of Cancer

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Indian Patent Office issues patent to bioAffinity Technologies for porphyrin compounds related to targeted cancer treatment.

6 months ago - Business Wire

bioAffinity Technologies In the News

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--A summary of latest news about bioAffinity Technologies and CyPath® Lung, its noninvasive test for the detection of early-stage lung cancer.

6 months ago - Business Wire

bioAffinity Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / January 5, 2024 / RedChip Companies will air interviews with bioAffinity Technologies, Inc. (NASDAQ:BIAF) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Mone...

Other symbols: BIVI
6 months ago - Accesswire

bioAffinity Technologies Appoints Jamie Platt, Ph.D., to its Board of Directors

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Jamie Platt, Ph.D., joins the bioAffinity Technologies Board of Directors.

8 months ago - Business Wire

CMS Posts Final Payment Determination for bioAffinity Technologies' CyPath® Lung Effective January 2024

SAN ANTONIO,--(BUSINESS WIRE)-- #BIAF--CMS has made a final determination for payment for CyPath® Lung, a noninvasive test for early-stage lung cancer, for the 2024 calendar year.

8 months ago - Business Wire

bioAffinity Technologies VP David Elzi, Ph.D., Named to American Society for Cell Biology Post

SAN ANTONIO--(BUSINESS WIRE)-- #ASCB--bioAffinity Technologies VP of Research David Elzi, Ph.D., named to post with the American Society for Cell Biology.

8 months ago - Business Wire

bioAffinity Technologies Teams with American Cancer Society to Raise Funds for Lung Cancer Screening

SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies today launched a campaign in partnership with the ACS to increase lung cancer screening in Texas.

8 months ago - Business Wire

bioAffinity Technologies Reports Third Quarter 2023 Financial Results and Provides Business Update

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports third quarter 2023 financial results and provides business update.

8 months ago - Business Wire

bioAffinity Technologies Names Dallas J. Coleman as National Director of Sales

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces the appointment of Dallas Coleman as National Director of Sales.

9 months ago - Business Wire